Clinical Observation On Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ: IgG Fc Fusion Protein Combined With Erteng Tongbi Mixture For Treatment Of Ankylosing Spondylitis

ObjeciveTo evaluate the elinieal efficacy of short-term treatment with recombinant human tumor necrosis factor-a receptorⅡ:IgG Fc fusion protein and Erteng Tongbi Mixturein ankylosing spondylitis.MethodsSixty patients who had active ankylosing spondylitis were randomized into two groups. The treatment group treated with recombinant human tumor necrosis factor- a receptorⅡ:IgG Fc fusion protein (25mg/times, two times for a week) first, after treatment for 4 weeks, changed the dose of(25mg/times, once a week)and Erteng Tongbi Mixture(15ml/times, three times a day). The control group treated w ith recombinant human tumor necrosis factor-αreceptorⅡ:IgG Fc fusion protein (25mg/times, two times for a week). During the course of treatment, all subjects were assessed at week 0,4,8,12 respectively.The observation items including proportion of BASFI, BASDAI score, PGV score, rachiodynia VAS, the time of lumbodorsal morning stiffness, thoracic expansion, Schober, finger-to-floor distance as well as CRP, ESR.ResultsThe observation items were all significantly improved after treatment in the treatment group (P<0.05), but in the control group improvement was only observed in the part items. Treatment group VS control group:After four weeks treatment, there was no significant difference between the two groups(P>0.05). After twelve weeks treatment, there was more improvement ofthe items and less occurrence of adverse reation were observed in the treatment group than that in the control group. The treatment group is obviously better than the control group in the aspects of alleviating the AS patient's BASFI, BASDAI score, PGV score, rachiodynia VAS, CRP, there were significances in statistics(P<0.05).GonclusionThe results had shown that Recombinant Human Tumor Necrosis Factor—αReceptorⅡ:IgG Fc Fusion Protein and Erteng Tongbi Mixture could provide substantial benefits to patients with active AS by reducing clinical signs and improving range of motion as well as quality of life, and was well tolerated in the treatment of AS patients.